AstraZeneca Plc: Wainua CARDIO-TTRansform Negative Surprise

Research evidence excerpt

AstraZeneca Plc: Wainua CARDIO-TTRansform Negative Surprise

Update

July 9, 2026 07:18 AM GMT

Morgan Stanley & Co. International plc+MAstraZeneca Plc | Europe Sarita Kapila

Equity Analyst

Wainua CARDIO-TTRansform Sarita.Kapila@morganstanley.comThibault Boutherin +44 20 7425-1320

Thibault.Boutherin@morganstanley.com +44 20 7425-9688

Negative Surprise Adithya Venkat

Research Associate

Adithya.Venkat@morganstanley.com +44 20 7425-2216

Key Takeaways

AstraZeneca Plc (AZN.L, AZN LN)

AZN announced CARDIO-TTRansform failed to meet its primary endpoint at Top Pick

Week 140. Wainua did not reduce the composite of CV mortality and recurrent ADRAZN.N

CV events Pharmaceuticals | United Kingdom

Stock Rating Overweight

In patients on standard of care, Wainua missed the primary endpoint; Industry View In-Line

monotherapy showed nominal benefit (HR 0.71), but no effect was seen on Price target 16,500p

Shr price, close (Jul 8, 2026) 14,240p

baseline stabiliser 52-Week Range 15,732-10,148p

Mkt cap, curr (mn) US$296,965

Consensus currently factors in ~$3.3bn risk-adjusted peak ATTR-CM sales for

Wainua; removing these sales represents a MSD%+ cut to consensus outer year

earnings

AstraZeneca and Ionis will present the full CARDIO-TTRansform data at the ESC

Congress in August 2026 following further analyses of the complete dataset

CARDIO-TTRansform fails to meet its primary endpoint, consensus earnings

likely to be cut MSD%. AstraZeneca announced today that Wainua (eplontersen)

did not demonstrate a statistically significant reduction in the composite of CV

mortality and recurrent CV events through week 140 in ATTR-CM. Although a

prespecified monotherapy subgroup achieved nominal significance (HR 0.71), no

treatment effect was observed in patients receiving stabiliser therapy at baseline.